256 related articles for article (PubMed ID: 37011399)
1. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
Kip KE; McCreary EK; Collins K; Minnier TE; Snyder GM; Garrard W; McKibben JC; Yealy DM; Seymour CW; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
Ann Intern Med; 2023 Apr; 176(4):496-504. PubMed ID: 37011399
[TBL] [Abstract][Full Text] [Related]
2. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
Trials; 2021 May; 22(1):363. PubMed ID: 34034784
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
[TBL] [Abstract][Full Text] [Related]
7. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
[TBL] [Abstract][Full Text] [Related]
8. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
Elife; 2022 Nov; 11():. PubMed ID: 36413383
[TBL] [Abstract][Full Text] [Related]
9. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
Ambrose N; Amin A; Anderson B; Barrera-Oro J; Bertagnolli M; Campion F; Chow D; Danan R; D'Arinzo L; Drews A; Erlandson K; Fitzgerald K; Garcia M; Gaspar FW; Gong C; Hanna G; Jones S; Lopansri B; Musser J; O'Horo J; Piantadosi S; Pritt B; Razonable RR; Roberts S; Sandmeyer S; Stein D; Vahidy F; Webb B; Yttri J
JAMA Netw Open; 2023 Apr; 6(4):e239694. PubMed ID: 37093599
[TBL] [Abstract][Full Text] [Related]
11. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
12. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study.
Knopp BW; Weiss HZ; Fahmy S; Goldstein E; Parmar J
Cureus; 2023 Aug; 15(8):e43094. PubMed ID: 37680398
[TBL] [Abstract][Full Text] [Related]
14. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Nakayama A; Zapf RL; Kip PL; Seymour CW; Huang DT
Contemp Clin Trials; 2022 Aug; 119():106822. PubMed ID: 35697146
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era.
McCreary EK; Kip KE; Collins K; Minnier TE; Snyder GM; Steiner A; Meyers R; Borneman T; Adam M; Thurau L; Yealy DM; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
Open Forum Infect Dis; 2022 Oct; 9(10):ofac517. PubMed ID: 36324319
[TBL] [Abstract][Full Text] [Related]
16. Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19.
Mazzotta V; Cozzi-Lepri A; Colavita F; Lanini S; Rosati S; Lalle E; Mastrorosa I; Cimaglia C; Vergori A; Bevilacqua N; Lapa D; Mariano A; Bettini A; Agrati C; Piselli P; Girardi E; Castilletti C; Garbuglia AR; Vaia F; Nicastri E; Antinori A
Front Immunol; 2022; 13():868020. PubMed ID: 35514955
[TBL] [Abstract][Full Text] [Related]
17. Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients.
Douin DJ; Wogu AF; Beaty LE; Carlson NE; Bennett TD; Aggarwal NR; Mayer DA; Ong TC; Russell S; Steele J; Peers JL; Molina KC; Wynia MK; Ginde AA
BMC Infect Dis; 2022 Nov; 22(1):818. PubMed ID: 36344927
[TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.
Cheng MM; Reyes C; Satram S; Birch H; Gibbons DC; Drysdale M; Bell CF; Suyundikov A; Ding X; Maher MC; Yeh W; Telenti A; Corey L
Infect Dis Ther; 2023 Feb; 12(2):607-621. PubMed ID: 36629998
[TBL] [Abstract][Full Text] [Related]
19. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele JD; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA
Chest; 2023 May; 163(5):1061-1070. PubMed ID: 36441040
[TBL] [Abstract][Full Text] [Related]
20. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
Front Immunol; 2021; 12():790469. PubMed ID: 34956222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]